EU AI Act

EU AI Act Article 50: What the Transparency Rules Require

EU AI Act Article 50 is now applicable, but it does not require one universal AI label. Learn how duties differ by organizational role, system, content type and exception.

💡

TL;DR:
Understand which EU AI Act Article 50 duties apply to providers, deployers and publishers—and when marking, disclosure or substantive human review matters.

What you need to know

The change: Certain providers and deployers now have distinct transparency duties.
Who is affected: Providers and deployers responsible for covered AI interactions, synthetic content, deepfakes, public-interest text, emotion recognition or biometric categorization.
Why it matters: Machine-readable marking and human-facing disclosure are different obligations.
What to do first: Classify each use case by organizational role, system or content type, and possible exception.
Key date or trigger: According to the European Commission, providers of systems placed on the market before August 2, 2026, have until December 2, 2026, to comply with Article 50(2)’s marking-and-detection obligation. The transition does not extend the other Article 50 duties.

This analysis continues in the PolicyEdge AI Intelligence Terminal, where members receive decision-grade intelligence on AI, regulation, and policy risk.

Founding Member access

Medicaid work requirements move along parallel pathways through three review points on a dark policy-intelligence grid.

Medicaid Work Requirements: What the Court Ruling Changes—and What It Doesn’t

A federal court declined to block three CMS provisions governing Medicaid work requirements. The ruling leaves the implementation timeline in place for now without resolving the legal merits.

June 2026 JOLTS report visual showing subtle labor-market signals without a clear hiring trend.

June 2026 JOLTS Report: Why the Data Do Not Show a Hiring Rebound

BLS reported job openings as little changed at 7.4 million and hires as unchanged at 5.3 million in June. The data did not establish a hiring rebound—and national estimates alone cannot determine whether a company’s critical roles are becoming easier to fill.

Trump generic-drug tariffs shown as cyan supply-chain paths crossing an amber threshold and branching into uncertain routes.

Trump Generic-Drug Tariffs: What Businesses Can—and Cannot—Plan For

Trump’s announced generic-drug tariffs could reshape supply chains beginning in 2028. Here is what manufacturers, healthcare purchasers and boards can assess now—and which unanswered policy questions prevent reliable forecasts.

Abstract blue and gold data flows contrast slower U.S. GDP growth with stronger private domestic demand.

U.S. GDP Growth Slowed, but Private Demand Accelerated

U.S. GDP growth slowed to 1.5% in Q2 2026, while BEA’s private-demand measure rose 3.9%. See what the divergence means for forecasts, AI investment, and risk.